Literature DB >> 9779768

Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis.

N Girgis1, Y Sultan, R W Frenck, A El-Gendy, Z Farid, A Mateczun.   

Abstract

OBJECTIVES: To evaluate the efficacy and safety of azithromycin compared with rifampin for eradication of nasopharyngeal carriage of Neisseria meningitidis
METHODS: Pharyngeal swabs were obtained from 500 students attending nursing school in Cairo, Egypt, to determine the colonization rate with N. meningitidis. Colonized individuals were randomized to receive azithromycin (500 mg once) or rifampin (600 mg twice daily for four doses). Subjects were then recultured 1 and 2 weeks posttreatment to determine the effectiveness of the antibiotic therapy for eradication of meningococcal nasopharyngeal colonization.
RESULTS: Individuals treated with azithromycin had a 93% eradication rate at 1 and 2 weeks posttreatment comparable with 95 and 91%, respectively, for rifampin. No significant side effects were reported by any subjects treated with either antibiotic.
CONCLUSION: Azithromycin is effective in the eradication of N. meningitidis from the nasopharynx of asymptomatic colonized individuals and deserves further evaluation for use as prophylaxis against N. meningitidis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779768     DOI: 10.1097/00006454-199809000-00013

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  12 in total

Review 1.  Infections diseases: meningococcal disease.

Authors:  C A Hart
Journal:  West J Med       Date:  2000-08

Review 2.  Pre-admission antibiotics for suspected cases of meningococcal disease.

Authors:  Thambu D Sudarsanam; Priscilla Rupali; Prathap Tharyan; Ooriapadickal Cherian Abraham; Kurien Thomas
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 4.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

5.  Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.

Authors:  Douglas J Biedenbach; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 6.  Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials.

Authors:  A Fraser; A Gafter-Gvili; M Paul; L Leibovici
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

Review 7.  Antibiotics for preventing meningococcal infections.

Authors:  Anca Zalmanovici Trestioreanu; Abigail Fraser; Anat Gafter-Gvili; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-25

8.  Shifts in the Antibiotic Susceptibility, Serogroups, and Clonal Complexes of Neisseria meningitidis in Shanghai, China: A Time Trend Analysis of the Pre-Quinolone and Quinolone Eras.

Authors:  Mingliang Chen; Qinglan Guo; Ye Wang; Ying Zou; Gangyi Wang; Xi Zhang; Xiaogang Xu; Miao Zhao; Fupin Hu; Di Qu; Min Chen; Minggui Wang
Journal:  PLoS Med       Date:  2015-06-09       Impact factor: 11.069

9.  Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.

Authors:  Corrado Blandizzi; Giuseppe Claudio Viscomi; Carmelo Scarpignato
Journal:  Drug Des Devel Ther       Date:  2014-12-16       Impact factor: 4.162

10.  Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease.

Authors:  Sanford R Kimmel
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.